Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to $154.9 million.

  • Theravance Biopharma's Short-term Investments rose 12786.14% to $154.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $154.9 million, marking a year-over-year increase of 12786.14%. This contributed to the annual value of $50.6 million for FY2024, which is 1960.53% down from last year.
  • Theravance Biopharma's Short-term Investments amounted to $154.9 million in Q3 2025, which was up 12786.14% from $56.9 million recorded in Q2 2025.
  • Theravance Biopharma's Short-term Investments' 5-year high stood at $154.9 million during Q3 2025, with a 5-year trough of $20.2 million in Q1 2025.
  • In the last 5 years, Theravance Biopharma's Short-term Investments had a median value of $60.0 million in 2021 and averaged $64.1 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first crashed by 8201.35% in 2021, then skyrocketed by 12786.14% in 2025.
  • Quarter analysis of 5 years shows Theravance Biopharma's Short-term Investments stood at $83.5 million in 2021, then crashed by 64.9% to $29.3 million in 2022, then surged by 114.52% to $62.9 million in 2023, then decreased by 19.61% to $50.6 million in 2024, then skyrocketed by 206.42% to $154.9 million in 2025.
  • Its Short-term Investments stands at $154.9 million for Q3 2025, versus $56.9 million for Q2 2025 and $20.2 million for Q1 2025.